Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of NSI 566 for the treatment of motor deficits caused by ischaemic stroke

Trial Profile

Phase I/II trial of NSI 566 for the treatment of motor deficits caused by ischaemic stroke

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 566 (Primary)
  • Indications Paralysis; Stroke
  • Focus Adverse reactions
  • Sponsors Neuralstem China
  • Most Recent Events

    • 01 Jul 2019 According to a Neuralstem media release, results from the phase I portion of this study was published in the Stem Cells Translational Medicine.
    • 01 Jul 2019 Results(n=9) of the phase I portion of this study published in the Neuralstem Media Release
    • 01 Jul 2019 According to a Neuralstem media release, the principal investigator of this study is Professor Xu Ruxiang.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top